Search

Your search keyword '"Qiao, Guaiping"' showing total 2 results
Start Over Author "Qiao, Guaiping" Topic 03 medical and health sciences
2 results on '"Qiao, Guaiping"'

1. Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia

Author

Wenqiang Cao, Li Han, Zhao Qianqian, Lei Tian, Xiaodong Ren, Yuling Ma, Hui Nan, Liu Yuzhi, Qiao Guaiping, Li Juan, Liang Chengyuan, and Hong Liu

Subjects
medicine.drug_class, Cellular differentiation, Retinoic acid, Antineoplastic Agents, Tretinoin, 01 natural sciences, 03 medical and health sciences, chemistry.chemical_compound, Leukemia, Promyelocytic, Acute, Drug Discovery, medicine, Humans, Retinoid, Receptor, neoplasms, PI3K/AKT/mTOR pathway, 030304 developmental biology, Cell Proliferation, Pharmacology, 0303 health sciences, 010405 organic chemistry, Chemistry, organic chemicals, TOR Serine-Threonine Kinases, Organic Chemistry, Autophagy, Cancer, General Medicine, medicine.disease, biological factors, 0104 chemical sciences, Cancer research, Acute promyelocytic leukaemia
Abstract

All-trans-retinoic acid (ATRA) is effective for preventing cancer and treating skin diseases and acute promyelocytic leukaemia (APL). These pharmacological effects of ATRA are mainly mediated by retinoid X receptors (RXRs) and retinoic acid receptors (RARs). This article provides a comprehensive overview of the clinical progress on and the molecular mechanisms of ATRA in the treatment of APL. ATRA can promote the transcriptional activation of differentiation-related genes and regulate autophagy by inhibiting mTOR, which results in anti-APL effects. In detail, the structures, pharmacological effects, and clinical studies of 68 types of ATRA analogues are described. These compounds have excellent antitumour therapeutic potential and could be used as lead compounds for further development and research.

Published
2020

2. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir

Author

Xie Xiaolin, Li Han, Lei Tian, Tang Yonghong, Zhang Dezhu, Zhenfeng Shi, Qiao Guaiping, Xu Zhao, Hui Nan, Liu Yuzhi, and Liang Chengyuan

Subjects
Drug, Emergency Use Authorization, Coronavirus disease 2019 (COVID-19), viruses, media_common.quotation_subject, Pneumonia, Viral, Review Article, Bioinformatics, medicine.disease_cause, Antiviral Agents, 01 natural sciences, Betacoronavirus, 03 medical and health sciences, Pharmacokinetics, Drug Discovery, Pandemic, medicine, Humans, Antiviral, Pandemics, 030304 developmental biology, media_common, Coronavirus, Pharmacology, Clinical Trials as Topic, 0303 health sciences, Alanine, SARS-CoV-2, 010405 organic chemistry, Chemistry, Organic Chemistry, COVID-19, General Medicine, Adenosine Monophosphate, COVID-19 Drug Treatment, 0104 chemical sciences, Clinical trial, RdRP inhibitor, Pharmacodynamics, Coronavirus Infections, Remdesivir (GS-5734)
Abstract

Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed., Graphical abstract Image 1, Highlights • This article provides a comprehensive overview of remdesivir (GS-5734). • Remdesivir inhibits a variety of RNA viruses, including Coronaviridae, Filoviridae, Paramyxoviridae and Arenaviridae . • The remdesivir synthetic routes were comprehensively collected and are presented as a compilation of roadmaps. • The mechanism and clinical trial information of remdesivir for the treatment of COVID-19 are summarized.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results